The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Uptake, outcomes, and costs of implementing non-invasive prenatal testing for Down's syndrome into NHS maternity care: prospective cohort study in eight diverse maternity units
Open accessAbstract
OBJECTIVE: To investigate the benefits and costs of implementing non-invasive prenatal testing (NIPT) for Down's syndrome into the NHS maternity care pathway. DESIGN: Prospective cohort study. SETTING: Eight maternity units across the United Kingdom between 1 November 2013 and 28 February 2015. PARTICIPANTS: All pregnant women with a current Down's syndrome risk on screening of at least 1/1000. MAIN OUTCOME MEASURES: Outcomes were uptake of NIPT, number of cases of Down's syndrome detected, invasive tests performed, and miscarriages avoided. Pregnancy outcomes and costs associated with implementation of NIPT, compared with current screening, were determined using study data on NIPT uptake and invasive testing in combination with national datasets. RESULTS: NIPT was prospectively offered to 3175 pregnant women. In 934 women with a Down's syndrome risk greater than 1/150, 695 (74.4%) chose NIPT, 166 (17.8%) chose invasive testing, and 73 (7.8%) declined further testing. Of 2241 women with risks between 1/151 and 1/1000, 1799 (80.3%) chose NIPT. Of 71 pregnancies with a confirmed diagnosis of Down's syndrome, 13/42 (31%) with the diagnosis after NIPT and 2/29 (7%) after direct invasive testing continued, resulting in 12 live births. In an annual screening population of 698 500, offering NIPT as a contingent test to women with a Down's syndrome screening risk of at least 1/150 would increase detection by 195 (95% uncertainty interval -34 to 480) cases with 3368 (2279 to 4027) fewer invasive tests and 17 (7 to 30) fewer procedure related miscarriages, for a non-significant difference in total costs (£-46 000, £-1 802 000 to £2 661 000). The marginal cost of NIPT testing strategies versus current screening is very sensitive to NIPT costs; at a screening threshold of 1/150, NIPT would be cheaper than current screening if it cost less than £256. Lowering the risk threshold increases the number of Down's syndrome cases detected and overall costs, while maintaining the reduction in invasive tests and procedure related miscarriages. CONCLUSIONS: Implementation of NIPT as a contingent test within a public sector Down's syndrome screening programme can improve quality of care, choices for women, and overall performance within the current budget. As some women use NIPT for information only, the Down's syndrome live birth rate may not change significantly. Future research should consider NIPT uptake and informed decision making outside of a research setting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The usefulness of this marker is limited by the uptake of trisomy screening, which is around 66% in the UK [12].”
From Volume and vascularity: Using ultrasound to unlock the secrets of the first trimester placenta (2019) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 24,214
Palomaki, G. E., Kloza, E. M., Lambert-Messerlian, G. M., Haddow, J. E., Neveux, L. M., Ehrich, M., van den Boom, D., Bombard, A. T., Deciu, C., Grody, W. W., et al. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3182368a0e · Cited by 937
Gil, M. M., Quezada, M. S., Revello, R., Akolekar, R., & Nicolaides, K. H. (2015) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.14791 · Cited by 822
Cell-free DNA Analysis for Noninvasive Examination of Trisomy
Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1407349 · Cited by 817
Update on Procedure-Related Risks for Prenatal Diagnosis Techniques
Tabor, A., & Alfirević, Ž. (2009) · Fetal Diagnosis and Therapy · doi:10.1159/000271995 · Cited by 398
Zhang, H., Gao, Y. M., Jiang, F., Fu, M., Yuan, Y., Guo, Y., Zhu, Z., Lin, M.-W., Liu, Q., Tian, Z., et al. (2015) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.14792 · Cited by 394
(2015) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001051 · Cited by 350
BENN, P. A., BORRELL, A., Chiu, R. W. K., Cuckle, H., Dugoff, L., Faas, B. H. W., Gross, S. J., Huang, T., Johnson, J.-A. M., Maymon, R., et al. (2015) · Prenatal Diagnosis · doi:10.1002/pd.4608 · Cited by 299
Self-citationACMG statement on noninvasive prenatal screening for fetal aneuploidy
Gregg, A. R., Gross, S. J., Best, R. G., Monaghan, K. G., Bajaj, K., Skotko, B. G., Thompson, B. H., & Watson, M. (2013) · Genetics in Medicine · doi:10.1038/gim.2013.29 · Cited by 272
Flagged first, then by citations
1 of the 40 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- [13]Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome--a cost sensitivity analysis. Prenat Diagn 2013; 33: 636- 42. 10.1002/pd.4157 pmid:23674341. 23674341 · DOI
- [14]Garfield SS, Armstrong SO. Clinical and cost consequences of incorporating a novel non-invasive prenatal test into the diagnostic pathway for fetal trisomies. J Managed Care Med 2012; 15: 34- 41.
- [35]National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. NICE, 2014 (available from https://www.nice.org.uk/article/pmg20/chapter/glossary#costconsequences-analysis). 26677490
Cited by
Sorted by citations
Items 101–149 of 149
Cell-free DNA and contingent screening: Our first year
Gomes, H. H., Lourenço, I. O., Ribeiro, J., Martins, D., Ribeiro, R., & Francisco, C. (2019) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2019.04.001 · Cited by 3
Evaluation of patient information leaflets for non-invasive prenatal testing for Down's syndrome
Daley, R., Hill, M. K., & Lewis, C. (2017) · British Journal of Midwifery · doi:10.12968/bjom.2017.25.9.585 · Cited by 3
Self-citationCost and efficacy comparison of prenatal recall and reflex DNA screening for trisomy 21, 18 and 13
Bestwick, J. P., & Wald, N. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220053 · Cited by 3
Public Health England and Co-Production with the Fetal Anomaly Screening Programme
Lloyd, C., Corcoran, E., & Murray, L. (2023) · The New Bioethics · doi:10.1080/20502877.2022.2147444 · Cited by 3
Wald, N., Huttly, W. J., Bestwick, J. P., Old, R. W., Morris, J. K., Cheng, R., Aquilina, J., Peregrine, E., Roberts, D., & Alfirević, Ž. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.256 · Cited by 3
Prenatal reflex DNA screening for trisomy 21, 18 and 13
Wald, N. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1462703 · Cited by 3
Naruse, K., Pooh, R. K., Kyukawa, Y., Tsunemi, T., & Yamada, T. (2023) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15740 · Cited by 2
Kelly, K. A., Leitão, S., Meaney, S., & O’Donoghue, K. (2023) · Journal of Genetic Counseling · doi:10.1002/jgc4.1769 · Cited by 2
Bülbül, G. A., Kirtiş, E., Kandemir, H., Sanhal, C. Y., Yakut, S., Karaüzüm, S. B., & Mendilcioğlu, İ. (2024) · Journal of Genetic Counseling · doi:10.1002/jgc4.1973 · Cited by 2
Shajpal, A., & Siddiqui, F. (2017) · Obstetrics Gynaecology & Reproductive Medicine · doi:10.1016/j.ogrm.2017.08.006 · Cited by 2
Hill, M. K., Ellard, S., Fisher, J., Fulop, N., Knight, M., Kroese, M., Ledger, J., Leeson‐Beevers, K., McEwan, A., McMullan, D. J., et al. (2022) · NIHR Open Research · doi:10.3310/nihropenres.13247.1 · Cited by 2
Self-citationNoninvasive prenatal testing/screening by circulating cell-free DNA
van Riel, M., Stanley, K. E., & Vermeesch, J. R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91380-5.00013-7 · Cited by 2
Rethinking second‐trimester Down‐syndrome screening in the cell‐free DNA era
Cuckle, H. (2019) · Ultrasound in Obstetrics and Gynecology · doi:10.1002/uog.20360 · Cited by 2
Walker, C. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.252 · Cited by 2
Regulating non-invasive prenatal testing (NIPT) for fetal sex determination
Taylor-Sands, M. M., Warton, C., & Bowman‐Smart, H. (2023) · Medical Law Review · doi:10.1093/medlaw/fwad014 · Cited by 1
Clinical applications and advancements in noninvasive prenatal diagnosis
Lee, S., Choi, J., Yun, J. H., Kang, S. H., Yu, J., Kang, J., Kim, C. Z., Ko, T. Y., & Yun, H. (2025) · Kosin Medical Journal · doi:10.7180/kmj.25.118 · Cited by 1
Large-scale implementation of non-invasive prenatal testing for fetal aneuploidies
Liu, J., Wu, M., He, S., Yang, L., 赵剑虹, Chen, Y., Tang, L., Zhao, C., Li, Y., Hao, G., et al. (2026) · Nature Health · doi:10.1038/s44360-026-00104-2 · Cited by 1
Díaz, B. R. (2019) · International Journal of Discrimination and the Law · doi:10.1177/1358229120902654 · Cited by 1
Impact of ultrasonography on identifying noninvasive prenatal screening false‐negative aneuploidy
Li, W., Zeng, F., Fan, B., Yu, N., Wu, J., Yang, Y., Huang, H., Li, S., & Peng, Z. (2020) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.1213 · Cited by 1
Conveying Information About Screening and Diagnosis
Hewison, J., Bryant, L. D., & Fisher, J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-7020-6956-7.00017-8 · Cited by 1
Self-citationDuvillier, C., Dard, R., Herve, B., Cohen, C., Vialard, F., & Quibel, T. (2021) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2021.10.002 · Cited by 1
Down sendromlu adölesanlarla aktiviteye katılım ve yaşam kalitesi
TEKİN, Ş. Ş., & Teki̇n, F. (2021) · Journal of Exercise Therapy and Rehabilitation · doi:10.15437/jetr.840003 · Cited by 1
Ethical Issues at the Beginning of Life
Holt, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-49250-6_9 · Cited by 1
Wald, N., & Old, R. W. (2018) · Journal of Medical Screening · doi:10.1177/0969141318781675 · Cited by 1
Blanquet, M., Dreux, S., Leger, S., Sault, C., Mourgues, C., Laurichesse‐Delmas, H., Lemery, D. J., Vendittelli, F., Debost‐Legrand, A., & MULLER, F. M. (2021) · Annales de biologie clinique · doi:10.1684/abc.2021.1656 · Cited by 1
Antenatal Screening for Down Syndrome: The Impact of NIPT
Bryant, L. D. (2019) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0028658 · Cited by 1
Sacco, A., & Pandya, P. P. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814189-2.00004-9
Stephen Morris, A., Clarke, C. S., & Hudson, E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814189-2.00016-5
Ghidini, A., & Chitty, L. S. (2018) · Prenatal Diagnosis · doi:10.1002/pd.5287
Self-citationReproductive Choice, in Context: Avoiding Excess and Deficiency?
Hull, R., & Shakespeare, T. (2019) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190622879.013.21
Fujimoto, A. B., Ayer, T., Caughey, A. B., & Keskinocak, P. (2020) · Prenatal Diagnosis · doi:10.1002/pd.5811
Lindquist, A., Hui, L., Poulton, A., Kluckow, E., Hutchinson, B., Pertile, M. D., Bonacquisto, L., Gugasyan, L., Kulkarni, A., Harraway, J. R., et al. (2021) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0000000000000883
Sahota, D. S., Tsang, F. H. K., Gu, J. S., Fung, W. K. V., Mok, K. Y., & Wong, C. L. (2021) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365513.2021.1929439
O'Reilly, O. (2024) · Figshare · doi:10.24385/lincoln.25159067
Jabeen, M. (2020) · InnovAiT Education and inspiration for general practice · doi:10.1177/1755738020931873
Hill, M. K., Ellard, S., Fisher, J., et al. (2022) · NIHR Open Research · doi:10.3310/nihropenres.14363.r28474
Non-invasive testing for Down's syndrome saves costs
(2016) · PharmacoEconomics & Outcomes News · doi:10.1007/s40274-016-3210-2
Hill, M. K., Ellard, S., Fisher, J., et al. (2022) · NIHR Open Research · doi:10.3310/nihropenres.14363.r28595
Hill, M. K., Ellard, S., Fisher, J., et al. (2022) · NIHR Open Research · doi:10.3310/nihropenres.14410.r28710
Bardi, F. (2022) · doi:10.33612/diss.245084236
Kudryavtseva, E. V., Kovalev, V. V., Baranov, I. I., & Dektyarev, A. A. (2022) · International Journal of Women s Health and Reproduction Sciences · doi:10.15296/ijwhr.2022.31
Fu, J., Zhong, X., Li, D., Ge, Y., & Zhang, X. (2023) · Journal of Medical Biochemistry · doi:10.5937/jomb0-33027
Chapter 3: Non-Invasive Prenatal Testing
Domenici, I. (2023) · Nomos Verlagsgesellschaft mbH & Co. KG eBooks · doi:10.5771/9783748918912-303
Noninvasive Prenatal Screening (NIPS) of Chromosomal Abnormalities
Chawla, L., & Thakur, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-6402-0_8
Ethical Issues at the Beginning of Life
Holt, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-54108-7_11
NIPT: Routine versus Considered Options
Ashutosh, G., Aneja, A., Bahl, N., Arora, R., & Nadir, L. (2024) · Journal of Fetal Medicine · doi:10.1055/s-0045-1808249
Mahajan, R. A., Magdum, H., Krishnamurthy, A., Verma, P., & Vineeth, V. (2026) · Journal of Marine Medical Society · doi:10.4103/jmms.jmms_131_25
Stevens, S., Broughan, J. M., Tempest, E., Mw, B., Permalloo, N., Brondel, G., Fleming, K. M., Mallinson, C., Miller, N., Springett, A., et al. (2026) · BMJ connections. · doi:10.1136/bmjccgg-2026-000089
Matallana, C. D. P., Sánchez‐Romero, J., Pertegal, M., Delgado⋈, J. L., Ramfjord, E., & Nicolaides, K. H. (2026) · Prenatal Diagnosis · doi:10.1002/pd.70260
Metadata
- Authors
- Chitty, L. S., Wright, D., Hill, M., Verhoef, T. I., Daley, R., Lewis, C., Mason, S., McKay, F., Jenkins, L., Howarth, A., Cameron, L., McEwan, A., Fisher, J., Kroese, M., & Morris, S.
- Affiliations
- Great Ormond Street Hospital (GB)
- University of Plymouth (GB)
- University College London (GB)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- PHG Foundation (GB)
- Nottingham University Hospitals NHS Trust (GB)
- Corresponding author
- Chitty, Lyn S
- ORCID
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2016-07-04
- Volume
- 354
- Pages
- i3426
- ISSN
- 1756-1833 (ISSN-L)
- PMC
- PMC4933930
- OpenAlex
- W2462899390
- Cited by
- 149
- References
- 40
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 11 · 2022: 11 · 2021: 14 · 2020: 16 · 2019: 26 · 2018: 20 · 2017: 30 · 2016: 6
- FWCI
- 31.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- BMJ (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- HighWire Press Open Archive (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0513-10141, RP-PG-0707-10107)
- Great Ormond Street Hospital Charity
- Programme Grants for Applied Research (RP-PG-0707-10107)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Screening and Diagnostics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Health Sciences › Medicine › Obstetrics and Gynecology › Maternal and Perinatal Health Interventions
- Keywords
- non-invasive prenatal testing, Down syndrome, prenatal screening, implementation costs, invasive prenatal diagnosis, miscarriage prevention, screening thresholds, diagnostic accuracy, pregnancy outcomes, cost-effectiveness, NHS Health Scotland
- MeSH terms
- Cost-Benefit Analysis, Down Syndrome, Female, Genetic Testing, United Kingdom, Humans, Maternal Age, Patient Acceptance of Health Care, Pregnancy, Pregnancy Outcome, Pregnancy Trimester, Second, Prenatal Diagnosis, Prospective Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review